Scancell

Scancell Ltd is a clinical-stage biopharmaceutical company pioneering next-generation cancer immunotherapies. Founded in 1996 as a spin-out from the University of Nottingham’s School of Medicine, Scancell has expertise in immunology, tumour-associated antigens, monoclonal antibody discovery, and DNA vaccine design. 

Its core technologies include ImmunoBody® DNA vaccines, which induce potent T cell responses in solid tumours, and Moditope®, targeting stress-induced modifications to trigger sustained immunity. 

Scancell also uses its GlymAb® antibody discovery platform, enhanced by AvidiMab® technology, to boost antibody potency and function. 

With multiple clinical-stage assets and recent licensing agreements demonstrating the commercial strength of its antibody portfolio, Scancell is building strategic partnerships to advance innovative immunotherapies that improve survival and quality of life for patients with hard-to-treat cancers.